VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-29.75%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$243M
AUM Growth
-$369M
(-60%)
Cap. Flow
-$185M
Cap. Flow
% of AUM
-76.23%
Top 10 Holdings %
Top 10 Hldgs %
9.9%
Holding
504
New
52
Increased
49
Reduced
307
Closed
94
Top Buys
| 1 |
Newmont
NEM
|
$1.82M |
| 2 |
COR
Coresite Realty Corporation
COR
|
$1.7M |
| 3 |
Public Storage
PSA
|
$1.53M |
| 4 |
Brookfield Renewable
BEP
|
$1.51M |
| 5 |
Avista
AVA
|
$1.44M |
Top Sells
| 1 |
Reliance Steel & Aluminium
RS
|
$4.3M |
| 2 |
Vale
VALE
|
$4.14M |
| 3 |
DEA
Easterly Government Properties
DEA
|
$4.07M |
| 4 |
NP
Neenah, Inc. Common Stock
NP
|
$4.04M |
| 5 |
Arbor Realty Trust
ABR
|
$3.91M |
Sector Composition
| 1 | Financials | 20.56% |
| 2 | Healthcare | 19.87% |
| 3 | Real Estate | 12.49% |
| 4 | Energy | 9.44% |
| 5 | Materials | 6.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
CytomX Therapeutics
CTMX
$376M
| $385K | 0.16% |
50,226
-7,311
| -13% | -$56K |
|
202
Corbus Pharmaceuticals
CRBP
$121M
| $374K | 0.15% |
2,378
-347
| -13% | -$54.6K |
|
|
RARX
203
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $365K | 0.15% |
7,612
-1,123
| -13% | -$53.8K |
|
204
Vanda Pharmaceuticals
VNDA
$272M
| $364K | 0.15% |
35,168
-2,968
| -8% | -$30.7K |
|
|
WPG
205
DELISTED
Washington Prime Group Inc.
WPG
| $364K | 0.15% |
+50,288
| New | +$364K |
|
206
Akero Therapeutics
AKRO
$3.58B
| $362K | 0.15% |
17,057
-2,474
| -13% | -$52.5K |
|
207
Ascendis Pharma
ASND
$12.5B
| $351K | 0.14% |
3,117
-452
| -13% | -$50.9K |
|
208
TG Therapeutics
TGTX
$5.11B
| $350K | 0.14% |
35,606
-5,183
| -13% | -$50.9K |
|
209
Apellis Pharmaceuticals
APLS
$3.55B
| $348K | 0.14% |
12,996
-1,892
| -13% | -$50.7K |
|
|
ODT
210
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $343K | 0.14% |
12,410
-1,819
| -13% | -$50.3K |
|
|
IMGN
211
DELISTED
Immunogen Inc
IMGN
| $342K | 0.14% |
100,431
-14,644
| -13% | -$49.9K |
|
|
RDUS
212
DELISTED
Radius Health, Inc.
RDUS
| $342K | 0.14% |
26,290
-2,219
| -8% | -$28.9K |
|
213
Arvinas
ARVN
$575M
| $341K | 0.14% |
8,462
-1,236
| -13% | -$49.8K |
|
|
SWTX
214
DELISTED
SpringWorks Therapeutics
SWTX
| $336K | 0.14% |
12,448
-1,805
| -13% | -$48.7K |
|
215
Adverum Biotechnologies
ADVM
$73.9M
| $333K | 0.14% |
3,411
-497
| -13% | -$48.5K |
|
216
Denali Therapeutics
DNLI
$2.26B
| $333K | 0.14% |
19,020
-2,785
| -13% | -$48.8K |
|
|
ICPT
217
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $325K | 0.13% |
5,156
-435
| -8% | -$27.4K |
|
218
AnaptysBio
ANAB
$613M
| $323K | 0.13% |
22,855
-3,331
| -13% | -$47.1K |
|
|
ARNA
219
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $321K | 0.13% |
7,650
-1,108
| -13% | -$46.5K |
|
|
KDMN
220
DELISTED
Kadmon Holdings, Inc.
KDMN
| $318K | 0.13% |
76,008
-11,086
| -13% | -$46.4K |
|
|
EPZM
221
DELISTED
Epizyme, Inc
EPZM
| $315K | 0.13% |
20,306
-2,966
| -13% | -$46K |
|
222
Zymeworks
ZYME
$1.14B
| $304K | 0.13% |
8,557
-1,252
| -13% | -$44.5K |
|
223
Y-mAbs Therapeutics
YMAB
$390M
| $296K | 0.12% |
11,332
-1,671
| -13% | -$43.6K |
|
224
Ardelyx
ARDX
$1.57B
| $292K | 0.12% |
51,359
-7,493
| -13% | -$42.6K |
|
|
CLVS
225
DELISTED
Clovis Oncology, Inc.
CLVS
| $291K | 0.12% |
45,754
-3,861
| -8% | -$24.6K |
|